Journal: Nature communications
This study defines a set of 31,744 CpG sites in blood that show highly stable DNA methylation patterns in young, healthy individuals, and then examines how disruption of these “epigenetically stable” loci relates to disease.
Key points:
- Discovery cohort: In young, healthy people, the authors identify CpG loci with very consistent methylation profiles, establishing a baseline of epigenetic stability in blood.
- Validation across 8,886 individuals: These loci are then analyzed in 29 cohorts, including:
- Hematologic malignancies (n=3,159; myeloid and lymphoid)
- Cardiovascular disease–related cohorts (n=2,788)
- Healthy controls (n=2,939)
- Hematologic cancers:
- Leukemia patients show clear disruption of methylation patterns at these normally stable CpGs.
- The degree of methylation disruption correlates with clonal burden and mutation frequency.
- Methylation changes track with treatment over time, suggesting a dynamic biomarker of disease activity and clone size.
- Non-cancer / cardiovascular cohorts:
- With aging, methylation at these stable loci becomes progressively more variable.
- Greater instability is associated with higher cardiovascular disease risk and poorer overall survival.
- Conceptual/mechanistic insight:
- Epigenetic instability at normally stable CpG sites appears to reflect the expansion of maladaptive hematopoietic clones.
- This provides a mechanistic link between DNA methylation dynamics, clonal hematopoiesis, and downstream disease (hematologic malignancy and cardiovascular events).
Implication for practice and research:
- Biomarker potential: These epigenetically stable CpG sites—and their loss of stability—represent a promising blood-based biomarker to:
- Detect and monitor hematologic cancers via clonal burden.
- Stratify cardiovascular risk and mortality in aging populations.
- Future directions: The work supports further development of methylation-instability assays as minimally invasive tools for early risk assessment and disease monitoring.